看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -24.2x - -26.8x | -25.5x |
| Selected Fwd P/E Multiple | -21.2x - -23.4x | -22.3x |
| Fair Value | kr287.85 - kr318.16 | kr303.01 |
| Upside | -37.6% - -31.1% | -34.4% |
| Benchmarks | - | Full Ticker |
| Genmab A/S | - | CPSE:GMAB |
| DBV Technologies S.A. | - | ENXTPA:DBV |
| Molecular Partners AG | - | SWX:MOLN |
| Basilea Pharmaceutica AG | - | SWX:BSLN |
| argenx SE | - | ENXTBR:ARGX |
| Zealand Pharma A/S | - | CPSE:ZEAL |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| GMAB | DBV | MOLN | BSLN | ARGX | ZEAL | |||
| CPSE:GMAB | ENXTPA:DBV | SWX:MOLN | SWX:BSLN | ENXTBR:ARGX | CPSE:ZEAL | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 29.4% | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | 38.4% | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 80.2% | -56.6% | 12.8% | 642.4% | 382.3% | -53.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 36.8% | -1752.3% | -564.0% | 2.2% | -225.4% | -758.9% | ||
| Prior Fiscal Year | 26.4% | -462.4% | -880.7% | 6.6% | -23.3% | -205.3% | ||
| Latest Fiscal Year | 36.4% | -2744.4% | -1087.4% | 37.2% | 37.1% | -1720.9% | ||
| Latest Twelve Months | 36.4% | -2744.4% | -1087.4% | 37.2% | 37.1% | -1720.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 8.9x | NA | 0.4x | 8.3x | -2185.9x | -18.6x | ||
| Price / LTM Sales | 4.0x | 59.4x | 24.4x | 2.6x | 17.5x | 510.8x | ||
| LTM P/E Ratio | 10.9x | -2.2x | -2.2x | 6.9x | 47.2x | -29.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -2.2x | 6.9x | 47.2x | |||||
| Historical LTM P/E Ratio | -29.7x | -13.3x | -6.8x | |||||
| Selected P/E Multiple | -24.2x | -25.5x | -26.8x | |||||
| (x) LTM Net Income | (1,079) | (1,079) | (1,079) | |||||
| (=) Equity Value | 26,160 | 27,537 | 28,914 | |||||
| (/) Shares Outstanding | 70.7 | 70.7 | 70.7 | |||||
| Implied Value Range | 370.13 | 389.61 | 409.09 | |||||
| FX Rate: DKK/DKK | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 370.13 | 389.61 | 409.09 | 461.60 | ||||
| Upside / (Downside) | -19.8% | -15.6% | -11.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GMAB | DBV | MOLN | BSLN | ARGX | ZEAL | |
| Value of Common Equity | 86,614 | 246 | 121 | 536 | 39,322 | 32,625 | |
| (/) Shares Outstanding | 62.3 | 136.7 | 36.9 | 12.1 | 61.1 | 70.7 | |
| Implied Stock Price | 1,390.00 | 1.80 | 3.29 | 44.20 | 643.99 | 461.60 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.13 | 1.00 | 1.00 | 1.13 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1,390.00 | 1.59 | 3.29 | 44.20 | 568.00 | 461.60 | |
| Trading Currency | DKK | EUR | CHF | CHF | EUR | DKK | |
| FX Rate to Reporting Currency | 1.00 | 1.13 | 1.00 | 1.00 | 1.13 | 1.00 | |